Diving into the latest from Deloitte, it’s clear: the Femtech world is buzzing with potential yet bumping into some familiar roadblocks. The vision for Femtech’s future is absolutely radiant, though investment, particularly at the growth stage, seems to tread more cautiously than we’d hope. The market's expected expansion to anywhere between $20 billion and a staggering $109 billion by 2032 tells us the sky's the limit. Personally, I see the horizon stretching even further as Femtech ventures beyond wellness into deeper research realms, challenging the old guard of the healthcare industry.
But here's the kicker – the investment landscape still feels like uncharted territory, especially when female founders find themselves nudged towards seeking female investors. It's a bit of a head-scratcher, considering we're addressing health issues that touch half the planet's population. Yet, here we are, navigating a world where Femtech is often pigeonholed, its financial backing seemingly earmarked for women-led funds, which, let's face it, are far from the majority.
This shift in perspective needs to start from the ground up, right from medical education to research focus. Angela VanScoy from Deloitte & Touche LLP hit the nail on the head: there’s ample room for Femtech to flourish, but we’re just scratching the surface due to the lack of women-centric research and education. Did you know women are nearly twice as likely to face adverse drug reactions? That’s because the bulk of our medications are based on trials primarily conducted on men.
The recent health initiatives by the Biden administration are steps in the right direction, small yet significant. They underscore a long-overdue acknowledgment: women's health needs serious catching up in the realm of research and development.
Let’s zoom out for a moment: The positive market signs for Femtech are there, and they're compelling. From hitting record pre-money valuations in 2022 to witnessing the first femtech financing rounds north of $100 million, the milestones are noteworthy. Yet, 2023 posed its challenges, aligning with broader investment market trends but also hinting at the resilience and potential rebound in 2024. The epicenters of investment, like the Bay Area, alongside emerging hubs in Salt Lake City, Fort Lauderdale, and Atlanta, tell us the story of a field that's just getting started.
In every data point, every deal, our drive at FemiSpace is to bolster women's health, shedding light on disparities and championing a future where women's healthcare is no longer an afterthought but a priority. Together, let’s dare, expand, and innovate in women's health.
#FemtechRising #DeloitteInsights #HealthcareInnovation #InvestInFemtech #FutureIsFemtech #WomenInHealthcare #InclusiveInvesting #FemtechGrowth #HealthTechPioneers #FemaleFoundersForward #InnovationForHer #FemiSpaceVision #EmpowermentThroughEducation #MarketPotential #FemtechOnTheRise #HealthcareEquity #FemiSpace #MarinaVieva
CFO at Rowden Technologies
1wSoooo… where did you rank?!! Congrats!!!